A proposal for the US Medicare program to lower payments for drugs granted accelerated approval stands out as the most innovative in a series of new administrative approaches that could rein in drug pricing.
FDA, CMS And Accelerated Approval: Flipping The Script
The US Medicare agency’s restrictive coverage policy for Alzheimer’s antibodies is a clear threat to the FDA accelerated approval pathway. Now the payor is going to try a different approach to strengthen the pathway.
